Last reviewed · How we verify
Novolin N
Novolin N is an intermediate-acting insulin that binds to insulin receptors on cells to facilitate glucose uptake and utilization, lowering blood glucose levels.
Novolin N is an intermediate-acting insulin that binds to insulin receptors on cells to facilitate glucose uptake and utilization, lowering blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Novolin N |
|---|---|
| Sponsor | Wockhardt |
| Drug class | Intermediate-acting insulin |
| Target | Insulin receptor |
| Modality | Biologic |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Novolin N (NPH insulin) is a suspension of insulin crystals complexed with protamine, which slows insulin absorption and extends its duration of action to 24 hours. It mimics the basal insulin secretion pattern of the pancreas, allowing sustained glucose control between meals and overnight. The drug works by activating insulin receptors on muscle, fat, and liver cells to promote glucose uptake and storage.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes (NA)
- Surgical or Medical Treatment (PHASE4)
- Clinical Study to Evaluate the Possible Efficacy of Metformin in Patients With Parkinson's Disease (PHASE2)
- The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination
- Avexitide for Treatment of Post-Bariatric Hypoglycemia (PHASE3)
- Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation (NA)
- Efficacy of Chromium Picolinate in Reducing Acanthosis Nigricans Severity in Adolescents With Insulin Resistance (NA)
- Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |